ARTICLE | Clinical News
Actimmune: Ph III STEADFAST data
December 14, 2016 10:56 PM UTC
Horizon discontinued development of Actimmune to treat Friedreich's ataxia after top-line data from the double-blind, U.S. Phase III STEADFAST trial in 92 patients showed that thrice-weekly subcutaneo...
BCIQ Company Profiles
BCIQ Target Profiles